Trial effectiveness of daily and weekly regimens after 12 wk of supplementation
Full sample
The comparison of trial effectiveness between the supplementation regimens included the effect of a potential differential level of compliance with the prescribed supplementation regimens. The comparisons are those between the allocation of daily and weekly regimens, disregarding the level of compliance. This type of analysis is often referred to as intention-to-treat analysis.
There was no significant difference in initial hemoglobin concentration between the weekly and daily supplementation groups at baseline (Table 2⇓). After 4, 8, and 12 wk of supplementation, hemoglobin concentrations had increased in both groups, but the increments were larger with the daily regimen. However, there was no significant difference between the groups in hemoglobin concentration after 12 wk of supplementation. Mean tablet intakes were 52 and 23 in the daily and weekly supplementation groups, respectively (P < 0.05). This corresponded to a compliance of 68% with the daily regimen and 104% with the weekly regimen (P < 0.05). The analysis was repeated by using a three-factor repeated-measures ANOVA (initial hemoglobin concentration, time of hemoglobin measurement, and supplementation regimen) including all interactions. As expected, initial hemoglobin concentration had a significant effect on the other hemoglobin measures (P < 0.05). Accounting for this and for a clustering effect within subjects, the mean hemoglobin concentration at 12 wk in the daily supplementation group (120.1 g/L) was significantly higher than that in the weekly supplementation group (117.1 g/L; P < 0.05).
Trial effectiveness of daily and weekly regimens after 12 wk of supplementation
Full sample
The comparison of trial effectiveness between the supplementation regimens included the effect of a potential differential level of compliance with the prescribed supplementation regimens. The comparisons are those between the allocation of daily and weekly regimens, disregarding the level of compliance. This type of analysis is often referred to as intention-to-treat analysis.
There was no significant difference in initial hemoglobin concentration between the weekly and daily supplementation groups at baseline (Table 2⇓). After 4, 8, and 12 wk of supplementation, hemoglobin concentrations had increased in both groups, but the increments were larger with the daily regimen. However, there was no significant difference between the groups in hemoglobin concentration after 12 wk of supplementation. Mean tablet intakes were 52 and 23 in the daily and weekly supplementation groups, respectively (P < 0.05). This corresponded to a compliance of 68% with the daily regimen and 104% with the weekly regimen (P < 0.05). The analysis was repeated by using a three-factor repeated-measures ANOVA (initial hemoglobin concentration, time of hemoglobin measurement, and supplementation regimen) including all interactions. As expected, initial hemoglobin concentration had a significant effect on the other hemoglobin measures (P < 0.05). Accounting for this and for a clustering effect within subjects, the mean hemoglobin concentration at 12 wk in the daily supplementation group (120.1 g/L) was significantly higher than that in the weekly supplementation group (117.1 g/L; P < 0.05).
การแปล กรุณารอสักครู่..